How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

43,734 results for

Hypertension Evaluation History

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

to severe hepatic impairment (Child-Pugh Class A-C) History of human immunodeficiency virus infection-associated PAH Prior exposure to sotatercept (ACE-011) or luspatercept (ACE-536) Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg during Screening Visit after a period of rest Systolic BP < 90 mmHg during Screening or at baseline History of known pericardial constriction Personal or family history of long (...) more. A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (PULSAR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03496207 Recruitment Status : Recruiting First Posted : April 12, 2018 Last

2018 Clinical Trials

162. Theory Construction and Effect of Intervention on Pregnant Women With Gestational Hypertension and Endocrine Disorders

number of saved studies (100). Please remove one or more studies before adding more. Theory Construction and Effect of Intervention on Pregnant Women With Gestational Hypertension and Endocrine Disorders The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details (...) Theory Construction and Effect of Intervention on Pregnant Women With Gestational Hypertension and Endocrine Disorders Theory Construction and Effect of Intervention on Pregnant Women With Gestational Hypertension and Endocrine Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2018 Clinical Trials

163. H-Type Hypertension Precision Medicine Trial

antihypertensive drugs; or for those who have not taken antihypertensive drugs within the last 2 weeks, two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP) ≥90 mmHg or systolic blood pressure (SBP) ≥140 mmHg (the second blood pressure was measured at V1); (3)If a study participant is a woman of childbearing age, she agrees to use a reliable contraceptive method during (...) in this study. Exclusion Criteria: Participants meeting any of the following criteria may not participate in this study: (1)Women who are pregnant and/or lactating; or women who intend to conceive within a year; (2)History of allergies to enalapril, folic acid or other components of the compound drug; (3)History of adverse reactions or intolerance to enalapril or other ACE inhibitors, or drugs or supplements containing folic acid; (4)Diagnosis or suspicion of secondary hypertension; (5)Known serious medical

2018 Clinical Trials

164. Surgical Idiopathic Intracranial Hypertension Treatment Trial

from a traumatic lumbar puncture, the patient can be discussed with the Study Director for possible inclusion.) Abnormal blood work-up indicating a medical or systemic condition associated with raised intracranial pressure Diabetes mellitus with diabetic retinopathy Ingestion of a drug or substance, or presence of a disorder, that has been associated with increased intracranial pressure within 2 months of diagnosis, such as lithium, vitamin A related products (e.g., Retin-A), or various cyclines (...) increased intracranial pressure are acceptable. Abnormal CSF contents: increased cells: > 8 cells; elevated protein: > 45 mg%; low glucose: < 30 mg% (If the lumbar puncture produces a cell count compatible with a traumatic needle insertion, the patient does not need to be excluded if the CSF white blood cell count (WBC) after correction is 8 cells/mm3 or less - see Manual of Procedures (MOP) for calculation. If > 8 cells or > 45mg% in CSF protein are documented in the CSF or calculated after conversion

2018 Clinical Trials

165. Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension

on the antenatal complications' for both mother and baby and the risks and benefits of administering antihypertensive therapy prior to delivery hypertension disorders of pregnancy often persist following delivery and sometimes arise de novo postpartum one of the maternal complications of pre eclampsia is residual chronic hypertension in about 1/3 of cases elevated blood pressure is seen in 6%to 8% of all pregnancies hypertension (arterial pressure >140/90 mmhg) in pregnancy is classified into one of four (...) hypertension in about 1/3 of cases elevated blood pressure is seen in 6%to 8% of all pregnancies hypertension (arterial pressure >140/90 mmhg) in pregnancy is classified into one of four conditions chronic hypertension that precedes pregnancy pre eclampsia and eclampsia: a systematic syndrome of elevated arterial pressure,proteinuria and other findings pre eclampsia superimposed upon chronic hypertension gestational hypertension or nonproteinuric hypertension of pregnancy evaluate the effectiveness, safety

2018 Clinical Trials

166. Response to Anti-hypertensives in Pregnant and Postpartum Patients

School of Medicine at Mount Sinai Collaborators: Mount Sinai Hospital, New York Maimonides Medical Center Information provided by (Responsible Party): Dyese Taylor, Icahn School of Medicine at Mount Sinai Study Details Study Description Go to Brief Summary: In this study, the investigators will evaluate the blood pressure response to nifedipine and labetalol in pregnant and postpartum patients, who present with hypertensive disease in pregnancy with severe range blood pressure defined as greater than (...) , if pregnant patients present with severe hypertension they are either given IV labetalol, IV hydralazine of nifedipine based on individual provider preference. There are few studies in the literature comparing oral nifedipine and IV labetalol with mixed data showing either they are equally effective or a faster time to achieving target blood pressure for patients who received nifedipine. In this study, the investigators will evaluate if there is a difference in time to achieve goal blood pressure

2018 Clinical Trials

167. Hemp Seed Protein Consumption for Hypertension

of Canada Manitoba Harvest Information provided by (Responsible Party): University of Manitoba Study Details Study Description Go to Brief Summary: This clinical trial is being conducted to study the effect of whole hemp seed protein, hemp seed protein hydrolysate derived bioactive peptide and casein protein consumption on systolic and diastolic ambulatory blood pressure. This study is will be conducted in 35 hypertensive participants aged between ≥18 and ≤75 yrs who have systolic blood pressure higher (...) index (AI) will be measured. Ambulatory blood pressure (ABP) over 24 hours will also be measured on day 1 of phase 1 and day 42 of each treatment period of the trial. Condition or disease Intervention/treatment Phase Hypertension Other: Whole hemp seed protein Other: Whole hemp seed protein plus bioactive peptides Other: Casein protein Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 35 participants Allocation

2018 Clinical Trials

168. Splenic Embolization for Portal Hypertension

Institute Information provided by (Responsible Party): University of Minnesota - Clinical and Translational Science Institute Study Details Study Description Go to Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of partial splenic artery embolization in the treatment of symptomatic portal vein hypertension. A secondary aim is to evaluate the relative efficacy of two separate splenic artery embolization techniques, coiling versus particle embolization of the spleen (...) Splenic Embolization for Portal Hypertension Splenic Embolization for Portal Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Splenic Embolization for Portal Hypertension The safety

2018 Clinical Trials

169. China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension

). Please remove one or more studies before adding more. China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension (CAMPUS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier (...) -reactive protein (CRP) values at study initiation and study completion Incidence of cardiovascular disease (CVD) events [ Time Frame: Month 12 ] Incidence of cardiovascular disease (CVD) events, including acute coronary syndrome, stable coronary artery disease, ischemic cardiomyopathy etc. Change from baseline in blood pressure levels [ Time Frame: Month 12 ] Change from baseline in systolic and diastolic blood pressure levels Changes from baseline in vascular endothelial function [ Time Frame: Month

2018 Clinical Trials

170. Comparisonbetween Primary Hypertension Monitoring Methods for Detection of Early Kidney Dysfunction

: Not yet recruiting First Posted : April 9, 2018 Last Update Posted : March 11, 2019 See Sponsor: Assiut University Information provided by (Responsible Party): Nader Nabil, Assiut University Study Details Study Description Go to Brief Summary: The present study aims to show the difference of blood pressure monitored centrally and automated BP monitoring among patients with primary hypertension for early detection of kidney dysfunction Condition or disease Intervention/treatment Primary Hypertension (...) Device: oscillometric device Detailed Description: Hypertension is well known as the silent killer, There is a close relationship between blood pressure levels and the risk of cardiovascular events, strokes and kidney disease. Diabetes and hypertension cause up to two-thirds of chronic kidney disease , chronic kidney disease is a common condition characterized by evidence of kidney damage or dysfunction. chronic kidney disease is currently classified based on a patient's estimated glomerular

2018 Clinical Trials

171. L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia

by whether a subject has feedings held within 72 hours of receiving oral L-citrulline administration for reasons not attributable to underlying condition Evaluate incidence of hypotension developing following L-citrulline administration [ Time Frame: 12 hours ] The safety outcome of tolerability of L-citrulline will be measured by whether a subject develops a decrease in blood pressure more than 25% below baseline within 12 hours of receiving a dose of oral L-citrulline for reasons not attributable (...) adding more. L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03542812 Recruitment Status : Not yet recruiting First Posted : May 31, 2018

2018 Clinical Trials

172. Cardio-ankle Vascular Index (CAVI) in Hypertension Patients After One Year of Treatment

Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Probability Sample Study Population The eligible patients were prospectively monitored to evaluate CAVI in hypertension treatment for every 3 months. All participants will be asked directly medical history, clinical examination and performed blood pressure measurement thoroughly. All clinical information will be retained in medical record. Criteria Inclusion Criteria (...) the conditions of the study will receive outpatient treatment Control group A group of normal people with the similar age to hypertension group was recruited as control group at the same time Outcome Measures Go to Primary Outcome Measures : CAVI score in hypertension group after one year of treatment [ Time Frame: 1 year ] CAVI score of patients who achieved their target blood pressure after one year of hypertension treatment Secondary Outcome Measures : Correlation between CAVI and smoking status [ Time

2018 Clinical Trials

173. A COmmunity and Tech-Based ApproaCh for Hypertension Self-MANagement

Healthy Volunteers: Yes Criteria Inclusion Criteria: self-identifying as African American age 30 years or older diagnosed with hypertension, with a blood pressure >140/80 mmHg prescribed at least one antihypertensive medication able to read and understand English own a smartphone Exclusion Criteria: history of cognitive impairment currently using a medication management app Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor (...) adherence, problem solving skills, patient-provider communication, and social support in an effort to improve blood pressure control. The investigators will conduct a two-arm randomized control trial (RCT) using a community participatory research approach and mixed methods to evaluate the efficacy of TBI intervention with community support (Coachman) compared to enhance usual care (ECU) among 40 African Americans with uncontrolled hypertension. The investigators aim to: Identify key content, design

2018 Clinical Trials

174. Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice

: bisoprolol/perindopril FDC Detailed Description: Multicenter observational open program. Assessment of the efficacy and tolerability of the fixed-dose combination of bisoprolol/perindopril in patients with arterial hypertension and stable CAD in daily clinical practice (STYLE) Study objectives and purposes: Primary endpoints: efficacy of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice regarding the BP efficacy of bisoprolol/perindopril FDC in patients with HT and stable (...) for MeSH terms Hypertension Heart Diseases Coronary Disease Coronary Artery Disease Myocardial Ischemia Vascular Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Bisoprolol Perindopril Antihypertensive Agents Sympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological

2018 Clinical Trials

175. Novel Mechanisms and Predictors of VEGF Receptor Inhibitor-Associated Hypertension

, 2018 Last Update Posted : October 17, 2018 See Sponsor: Vanderbilt University Medical Center Information provided by (Responsible Party): Joshua Beckman, Vanderbilt University Medical Center Study Details Study Description Go to Brief Summary: The purpose of this study is to understand the effect of VEGF inhibitor treatment on blood pressure and blood vessel function. Condition or disease Intervention/treatment Renal Cell Carcinoma Hypertension Diagnostic Test: Ambulatory Blood Pressure Measurement (...) and Cohorts Go to Group/Cohort Intervention/treatment Patients receiving VEGFR 2 Inhibitor Assessments will be made before and after patients receive VEGF Receptor 2 Kinase Inhibitor. Patients are receiving the VEGF receptor as part of standard of care. Diagnostic Test: Ambulatory Blood Pressure Measurement Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate

2018 Clinical Trials

176. A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure

must have been diagnosed with essential hypertension for a minimum of 3 months prior to screening At Screening, on a stable regimen of antihypertensive medications for at least 1 month prior to screening Agree to conduct at home BP and HR monitoring three times weekly and document the average of the triplicate measurements assessed on a day in the patient diary Exclusion Criteria Clinically-significant (CS) abnormalities in medical history, screening laboratory results, physical or physical (...) , 2018 Last Update Posted: March 25, 2019 Last Verified: March 2019 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by Ionis Pharmaceuticals, Inc.: Hypertension Hypertensive AGT Angiotensinogen Blood Pressure High Blood Pressure Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Vascular Diseases

2018 Clinical Trials

177. Prevalence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism : (Preva-CTEPH)

). Please remove one or more studies before adding more. Prevalence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism : (Preva-CTEPH) (Preva-CTEPH) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier (...) is to evaluate the cumulative incidence of CTEPH after a PE. Condition or disease Intervention/treatment Phase Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pulmonary Embolism Diagnostic Test: Study population Not Applicable Detailed Description: The patients selected in this study are patients with an objectively confirmed PE and previously included since at least 12 months in one of the studies of the INNOVTE network. Patients who are alive at the time of the selection for the PREVA-CTEPH study

2018 Clinical Trials

178. Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. Mechanistic studies are needed to define specific biologic targets and thus optimize therapeutic benefits. Type 2 (...) for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Experimental will receive two bottles of Ertugliflozin 15mg tablets (active drug) and a placebo for hydrochlorothiazide. Drug: Ertugliflozin The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes

2018 Clinical Trials

179. Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study

), chronic thromboembolic pulmonary hypertension (WHO PH group 4), or unclear multifactorial mechanisms (WHO PH group 5). Known or suspected pulmonary veno-occlusive disease (PVOD). Severe restrictive lung disease (Total Lung Capacity <60% predicted) Severe obstructive lung disease (FEV1/FVC < 60% after a bronchodilator) DLCO <40% Systolic blood pressure <90 mmHg Resting heart rate in the awake patient <50 BPM or >110 BPM Clinically unstable right heart failure within the last 3 months or are WHO FC IV (...) Arterial Hypertension: a Pilot Study (APPRoAcH-p) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03655704 Recruitment Status : Not yet recruiting First Posted : August 31, 2018 Last Update Posted : January 23, 2019 See

2018 Clinical Trials

180. Whole Exome Sequencing in CKD Hypertension

Affiliated Hospital, Sun Yat-Sen University Information provided by (Responsible Party): Cheng Wang, Fifth Affiliated Hospital, Sun Yat-Sen University Study Details Study Description Go to Brief Summary: The prevalence of hypertension in patients with CKD in China is high but the control rate is low. Compared with the single blood pressure measurement method of the blood pressure of the office, ambulatory blood pressure monitoring (ABPM) can reflect the overall situation of 24-hour blood pressure (...) that in the CKD population, elevated nighttime blood pressure is more predictive of CKD progression or CVD than daytime blood pressure. Compared with countries such as Europe and the United States, there are differences in the causes, genetic background and daily behaviors of kidney disease in our population. It is urgent to investigate the predictive value of nocturnal hypertension for renal end point and CVD in CKD population in China. To this end, our study found for the first time that CKD patients

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>